Hims & Hers will stop selling some weight loss drugs — and the stock plummets 27%
Hims & Hers (HIMS) stock took a steep dive, dropping more than 27%Tuesday morning — even after the millennial-focused ...
Hims & Hers shares plunge 28% on concerns over weight loss business, margins
Hims & Hers on Monday released fourth-quarter results that disappointed on gross margin and sparked concerns about the future ...
NBC2650m
Hims and Hers likely to stop selling cheaper versions of GLP-1 medications
The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded versions due to regulatory changes.
ENDPOINTS NEWS56m
Is the GLP-1 com­pound­ing boom over? Not ex­act­ly
FDA ends semaglutide shortage, impacting compounding pharmacies. Hims & Hers plans personalized versions while Olympia ...